Statistics on dispensed medicines reimbursable under the National Health Insurance scheme (OFS)
The statistics on dispensed medicines reimbursable under the National Health Insurance scheme are based on medicine purchases reimbursed at the pharmacy.
The statistics cover data on dispensations of reimbursable medicines, the costs associated with them, and the reimbursements potentially paid for them.
Latest release
16 June 2026
Medicine sales amounted to a total of EUR 4.2 billion in 2025, which marks an increase of 4%, or EUR 165 million, from the previous year. Sales of prescription medicines in outpatient care amounted to EUR 2,924 million (an increase of 6%), sales of over-the-counter medicines to EUR 402 million (an increase of 1%), and wholesale sales to hospitals and other institutions to EUR 873 million (a decrease of 1%). Semaglutide, a medicine used to treat diabetes and obesity, remains the best-selling medicinal product when measured in euros.
In 2025, customers purchased reimbursable medicines for a total amount of EUR 2.74 billion. Kela paid out a total of EUR 1.98 billion in medicine cost reimbursements. This translates into an increase of 4% (EUR 78 million) on the previous year.
The expenditure on reimbursements for medicines reimbursed at the basic rate amounted to EUR 400 million of the total amount of medicine cost reimbursements. This marked an increase of 5% on the previous year. On the other hand, Kela’s expenditure on reimbursements for medicines reimbursed at a special rate of reimbursement amounted to a total of EUR 1,259 million. Of this sum, the expenditure on medicines reimbursed at the higher special rate was EUR 803 million, while the expenditure on medicines reimbursed at the lower special rate was EUR 456 million. The reimbursements paid for medicines reimbursed at the higher special rate grew by 8%, while those paid for medicines reimbursed at the lower special rate decreased by 5% from the previous year.
Finnish statistics on medicines 2025 (julkari.fi)
News: Pharmaceutical sales increase by EUR 165 million in 2025 – growth due to new medicines and new uses
Statistical publications
- Finnish Statistics on Medicines
- Kela Statistical Yearbook
- Kela’s Pocket Statistics
- Kela’s statistics in charts
Statistical Database Kelasto
Click the link to generate a dynamic and editable report from the database.
How to work with reports in Kelasto.
- Dispensations reimbursable under the NHI scheme
- Reimbursements of medicine expenses: Number of recipients and prescription data
- Filled prescriptions of reimbursable medicines according to prescriber 2020–
Additional information
Contact information
Otto Kontio
Lauri Manninen
tilastot@kela.fi
